TABLE 2.

Responses to individual NS3 peptides from pp2 (first four peptides listed) and pp3 (last four peptides listed) that consistently induced IFN-γ-producing cells in at least one of the animals

Peptide location (aa)Peptide sequenceaIFN-γ productionb
PrechallengePostchallenge
Vac1Vac2Vac1Vac2Ctrl
1156RPVSYLKGSSGGPLLc<20
1172PSGHVVGIFRAAVCTc<20
1252RVLNPSVAATLGFGAd<20<20<20
1268MSKAHGIEPNIRTGVc<20
1364EVALSNTGEIPFYGKc<20
1372EIPFYGKAIPIEAIK20-39>4020-39
1380IPIEAIKGGRHLIFC20-3920-39
1388GRHLIFCHSKKKCDEc,d20-39<20<20
  • a The overlapping sequences are underlined.

  • b Results shown are the number of IFN-γ spots per million cells. —, no IFN-γ production detected at week 47 (prechallenge) and week 8 postchallenge. The major histocompatability complex class I typing of the chimpanzees (Patr class I) is as follows: for Vac1, A−, B*0201, C*0601, and A*0601, B*0101, C*0401; for Vac2, A*0401, B*1401, C*0203 and A*1401, B*16011, C*0502; and for the control animal, A*0601, B*0301, C*0901 and A*0401, B*0101, C*0401.

  • c Peptides covering previously described human CD8 epitopes.

  • d Peptides covering previously described human CD4 epitopes.